GATES FOUNDATION ACCURATELY FORECAST CORONAVIRUS OUTBREAK IMMEDIATELY PRIOR TO WUHAN! 

HOW CLEVER WAS THAT?

https://www.google.com/search?q=GATES+FOUNDATION+images&rlz=1C1ARAB_enGB463GB464&sxsrf=ALeKk01_sXGOrdVsK6i02xyEa00iosXvLg:1612531872834&tbm=isch&source=iu&ictx=1&fir=Jluc2FwYZtiBQM%252C4YhDl9zTqcjWBM%252C_&vet=1&usg=AI4_-kQ0mtZVofzIix0B7vDwdJMROzbWfA&sa=X&ved=2ahUKEwjKiOCr7dLuAhXFRxUIHf6ADRQQ9QF6BAgIEAE&biw=1280&bih=881#imgrc=Jluc2FwYZtiBQM

The following from: https://www.expertinalllegalmatters.com/coronavirus-and-5g-are-linked?

Bill and Melinda Gates Foundation, others, predicted 65 million deaths from Coronavirus in October 2019 simulation PRIOR to the Wuhan outbreak. 

Foundation also funded group who owns virus patent and is funding research for a vaccine to stop it from spreading.

PATENT No.:   US  7,220,852 B1

Date of Patent: May 22, 2007

Inventors:  22 named individuals.

Assignee: U.S.A and C.D.C

ABSTRACT:

Disclosed herein is a newly isolated human Coronavirus (SARS-CoV) , the causative agent of  Severe Acute Respiratory Syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.

Timeline
Application US10/822,904 events
2003-04-25  – Priority to US46592703P
2004-04-12 –  Application filed by Centers of Disease Control and Prevention (Department of Health and Human Services)

2004-04-12 – Priority to US10/822,904
2007-05-22 – Application granted
2007-05-22 – Publication of US7220852B1
2007-06-28 – Assigned to THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION

2020-01-22 – Application status is Expired – Fee Related
2024-04-12 – Anticipated expiration

Info :  Patent citations (3) Non-patent citations (16) Cited by (8) Legal events Similar documents Priority and Related Applications External links :  USPTO, USPTO Assignment Espacenet Global Dossier Discuss

Page 1 / 72
Zoom 100%

[Coronavirus isolated from humans, patent timeline]

 
January 23, 2020

The Bill and Melinda Gates Foundation co-hosted a pandemic exercise in late 2019 that simulated a global coronavirus outbreak.

They also just happen to fund the group who owns the patent to the deadly virus and are working on a vaccine to solve the crisis.

On June 19, 2015, the UK government-funded Pirbright Institute filed an application for a patent for the live coronavirus, which was approved on Nov 20, 2018.

Suspiciously, a Pirbright Institute “primary funder” is the Bill and Melinda Gates Foundation.

Specifically, the Bill and Melinda Gates Foundation donated $189,232 to the Pirbright Institute in a 2013 grant looking “to improve our understanding of, and effective use of, current control tools and measures (including vaccines) against peste des petits ruminants and foot and mouth disease, two serious diseases affecting livestock that are widespread in developing countries.”

Then, in November of 2019, the Pirbright Institute’s website published an article focusing on the Bill & Melinda Gates Foundation’s funding of “a Livestock Antibody Hub” to the sum of $5.5 million.

“The ambitious programme of work will see extensive collaboration between multiple UK research organisations in order to utilise research outcomes in livestock disease and immunology to support human health as part of the ‘One Health’ agenda,” the Pirbright Institute wrote last November.

Professor John Hammond, the lead researcher on the program, said, “New technology has given us the opportunity to utilise these detailed antibody responses to make the next generation of vaccines and therapies, which will improve animal health and ultimately human health, as well as ensuring the security of our food supply.”

Pirbright Institute Hires Coronavirus Expert To Work With Livestock Antibody Hub

Additionally, at the same time the Pirbright Institute announced the Livestock Antibody Hub program, they posted a job opening for a 4-year Postdoctoral Scientist position on LinkedIn.com.

The advertisement for the job opening explains, “The post-holder will report to the Heads of the Coronavirus Group and the Viral Oncogenesis Group work and will work closely with a multidisciplinary team to advance the aims of the overall Pirbright Livestock Antibody Hub.”

Keep in mind, this all took place prior to the current Wuhan coronavirus outbreak.

Bill And Melinda Gates Behind Global Pandemic Exercise Focusing On Coronavirus

Meanwhile, on Oct. 18, 2019, also before the outbreak, the Bill and Melinda Gates Foundation, the Johns Hopkins Bloomberg School of Public Health and the World Economic Forum co-hosted an event in NYC where “policymakers, business leaders, and health officials” worked together on a simulated coronavirus outbreak.

Titled the “Event 201” pandemic, the high-level pandemic exercise “dropped participants right in the midst of an uncontrolled coronavirus outbreak that was spreading like wildfire out of South America to wreak worldwide havoc.”

“In the simulation, CAPS (the coronavirus) resulted in a death toll of 65 million people within 18 months,” according to John Hopkins University.

A video highlight reel from the event shows fictional newscasters from “GNN” discuss how the hypothetical immune-resistant virus (nicknamed CAPS) was crippling trade and travel, sending the global economy into freefall.

It just so happens that a professor from Imperial College London recently warned the coronavirus has the same kill rate as the Spanish flu, which claimed the lives of 20-50 million people in 1918.

Coronavirus is a Patented Virus

Below is a quick list of patents which deal with this ‘new’ coronavirus. There is a pretty recent patent as of July 4th, 2019 with this coronavirus. We know how most of these viruses are lab created and this provides some more reach or information to research.

• CORONAVIRUS PROTEINS AND ANTIGENS Publication number: 20160339097 Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhoea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition. Type: Application Filed: August 4, 2016 Publication date: November 24, 2016 Applicant: MJ Biologics, Inc. Inventor: Byoung-Kwan Kim

• CORONAVIRUS PROTEINS AND ANTIGENS Publication number: 20190202868 Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhoea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition. Type: Application Filed: March 15, 2019 Publication date: July 4, 2019 Applicant: Phibro Animal Health Corporation Inventor: Byoung-Kwan Kim

• Coronavirus proteins and antigens Patent number: 10280199 Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhoea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition. Type: Grant Filed: August 4, 2016 Date of Patent: May 7, 2019 Assignee: Phibro Animal Health Corporation Inventor: Byoung-Kwan Kim

• Vaccine compositions and methods of treating coronavirus infection Publication number: 20060286124 Abstract: The present disclosure relates to compositions and methods for treating or preventing coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, fragment, or variant thereof, capable of eliciting a protective humoral and/or cell-mediated immune response, which compositions are useful for treating or preventing infection by coronavirus, such as the causative agent of SARS. Also, coronavirus S protein and N protein immunogen compositions are provided that include an adjuvant, such as Proteosome or Protollin, which may be used for treating or preventing infection caused by a coronavirus, such as a SARS coronavirus. Type: Application Filed: June 30, 2005 Publication date: December 21, 2006 Applicant: ID Biomedical Corporation of Quebec Inventors: David Burt, Mark Reddish, Mary Hu, George Lowell, David Jones

• Uncharacterised ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy Publication number: 20050276818 Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus. Type: Application Filed: May 17, 2005 Publication date: December 15, 2005 Inventors: Adam Godzik, Sergey Sikora

• Uncharacterised ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy Patent number: 7504205 Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus. Type: Grant Filed: May 17, 2005 Date of Patent: March 17, 2009 Assignee: The Burnham Institute Inventors: Adam Godzik, Sergey Sikora

• Inactivated canine coronavirus vaccine Patent number: 4567042 Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed. Type: Grant Filed: June 7, 1984 Date of Patent: January 28, 1986 Assignee: American Home Products Corporation Inventors: William M. Acree, Bobby Edwards, John W. Black

• CANINE RESPIRATORY CORONAVIRUS (CRCV) SPIKE PROTEIN, POLYMERASE AND HEMAGGLUTININ/ESTERASE Publication number: 20090081780 Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43. Type: Application Filed: September 26, 2008 Publication date: March 26, 2009 Applicant: The Royal Veterinary College Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles

• PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS CORONAVIRUS AND APPLICATION THEREOF Publication number: 20100304363 Abstract: Disclosed herein are peptide compounds and the application thereof to the detection and inhibition of SARS coronavirus. Composed of dipeptides, the compounds for detecting and inhibiting SARS coronavirus can be readily synthesised and produced at low cost. In addition, they can be stored safely for a long period of time. The dipeptide compounds are useful as inhibitors of SARS coronavirus as well as acting as excellent capturing materials of SARS coronavirus. Type: Application Filed: May 26, 2010 Publication date: December 2, 2010 Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE Inventors: Soo-Hyung LEE, Hyo-Bong Hong, Tao-Wan Kim, Myung-Ae Chung, Sung-Woo Sohn, Seoung-Min Yoo

• Canine Respiratory Coronavirus (Crcv) Spike Protein, Polymerase and Hemagglutinin/Esterase Publication number: 20070248616 Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g. Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14). Type: Application Filed: July 1, 2003 Publication date: October 25, 2007 Inventors: John Brownlie, Victoria Chalker, Kerstin Erles

• Canine respiratory coronavirus (CRCV) spike protein Patent number: 7981427 Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43. Type: Grant Filed: September 26, 2008 Date of Patent: July 19, 2011 Assignee: The Royal Veterinary College Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles

• Methods and compositions for infectious cDNA of SARS coronavirus Publication number: 20060240530 Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids. Type: Application Filed: January 19, 2006 Publication date: October 26, 2006 Inventors: Ralph Baric, Rhonda Roberts, Boyd Yount, Kristopher Curtis

• Compositions and methods for detecting severe acute respiratory syndrome coronavirus Publication number: 20050095582 Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus. Type: Application Filed: November 3, 2003 Publication date: May 5, 2005 Applicants: Diagnostic Hybrids, Inc., Health Research Incorporated Inventors: Laura Gillim-Ross, Jill Taylor, David Scholl, David Wentworth, Joseph Jollick Compositions and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus Publication number: 20080076115 Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus. Type: Application Filed: November 3, 2004 Publication date: March 27, 2008 Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth

• Compositions And Methods For Detecting Severe Acute Respiratory Syndrome Coronavirus Publication number: 20110223659 Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus. Type: Application Filed: December 7, 2010 Publication date: September 15, 2011 Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth

• Ribozyme to cleave coronavirus gene Publication number: 20100273997 Abstract: Provided is a ribozyme to cleave a coronavirus gene and a therapeutic agent for a coronavirus infectious disease. A common base sequence in coronaviruses such as SARS-CoV and MHV was searched to design a ribozyme including a base sequence complementary thereto. Moreover, a therapeutic agent for a coronavirus infectious disease including such ribozyme was obtained. Type: Application Filed: August 9, 2006 Publication date: October 28, 2010 Inventors: Noboru Fukuda, Takahiro Ueno, Akiko Fukushima, Kazumichi Kuroda

• Compositions and methods for treating coronavirus infection and SARS Publication number: 20050002901 Abstract: The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection. Type: Application Filed: March 30, 2004 Publication date: January 6, 2005 Inventor: Lawrence Blatt

• FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS STRUCTURAL PROTEINS, THEIR PRODUCTION AND USES Publication number: 20100150923 Abstract: Fusion proteins of recombinant SARS coronavirus structural proteins, their production and uses are provided. An optimised SARS coronavirus S protein gene which can be highly expressed in the mammalian cell strains and SARS coronavirus S protein variants comprising deletion, modification or mutation amino acids 318-510 corresponding to SARS coronavirus S protein are also provided. Type: Application Filed: June 13, 2006 Publication date: June 17, 2010 Applicant: Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences Inventors: Chengyu Jiang, Feng Guo, Shuan Rao, Bing Guan, Yi Huan, Peng Yang

• Civet animal model system for Severe Acute Respiratory Syndrome (SARS) coronavirus infection and uses thereof Publication number: 20060123499 Abstract: The present invention is directed towards the use of the masked palm civet Paguma larvata (“civet”) as an animal model system for SARS, and is based on the novel demonstration of the present invention that civets may be infected with exogenous coronavirus, and that such infection produces SARS-like symptoms in these infected animals. The present invention is directed to a civet model system for the study of the infection, replication, and clinical effects of exogenously introduced human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof, and to the development of vaccines (or other methods of prevention) or treatment of infection or transmission to other civets or humans of these human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof. Type: Application Filed: December 6, 2004 Publication date: June 8, 2006 Inventors: Donglai Wu, Xiangang Kong, Qingwen Meng, Yonggang Liu, Yuntao Guan, Xunnan Yin, Mouping Wang, Changwen Li, Ming Liao, Chao-an Xin, Jinding Chen, Changchun Tu, Hua Xuan, Yedong Yu

• METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS AND THERAPEUTICS Publication number: 20160238601 Abstract: The present invention provides methods and compositions for detecting a coronavirus in a sample and identifying the subgroup of the coronavirus in the sample. Type: Application Filed: October 14, 2014 Publication date: August 18, 2016 Inventors: Ralph Baric, Sudhakar Agnihothram, Boyd Yount

Chronology
1890
Bovine coronavirus and canine respiratory coronavirus diverged from a common ancestor in 1951. Bovine coronavirus and human coronavirus OC43 diverged in 1899. Bovine coronavirus diverged from the equine coronavirus species at the end of the 18th century. Another estimate suggests that human coronavirus OC43 diverged from bovine coronavirus in 1890.

1986
The most closely related bat coronovirus and the SARS coronavirus diverged in 1986. A path of evolution of the SARS virus and keen relationship with bats have been proposed. The authors suggest that the coronaviruses have been coevolved with bats for a long time and the ancestors of SARS virus first infected the species of the genus Hipposideridae, subsequently spread to species of the Rhinolophidae and then to civets, and finally to humans.

2003
Coronaviruses primarily infect the upper respiratory and gastrointestinal tract of mammals and birds. Currently there are seven known strains of Coronaviruses that infect humans. Coronaviruses are believed to cause a significant percentage of all common colds in human adults and children. Coronaviruses cause colds with major symptoms, e.g. fever, throat swollen adenoids, in humans primarily in the winter and early spring seasons. Coronaviruses can cause pneumonia, either direct viral pneumonia or a secondary bacterial pneumonia, and bronchitis, either direct viral bronchitis or a secondary bacterial bronchitis. The much publicised human coronavirus discovered in 2003, SARS-CoV which causes severe acute respiratory syndrome (SARS), has a unique pathogenesis because it causes both upper and lower respiratory tract infections. The significance and economic impact of coronaviruses as causative agents of the common cold are hard to assess because, unlike rhinoviruses (another common cold virus), human coronaviruses are difficult to grow in the laboratory.

2003
Coronaviruses were discovered in the 1960s; the earliest ones discovered were infectious bronchitis virus in chickens and two viruses from the nasal cavities of human patients with the common cold that were subsequently named human coronavirus 229E and human coronavirus OC43. Other members of this family have since been identified, including SARS-CoV in 2003, HCoV NL63 in 2004, HKU1 in 2005, MERS-CoV in 2012, and 2019-nCoV in 2019; most of these have been involved in serious respiratory tract infections.

2003
In 2003, following the outbreak of severe acute respiratory syndrome (SARS) which had begun the prior year in Asia, and secondary cases elsewhere in the world, the World Health Organisation (WHO) issued a press release stating that a novel coronavirus identified by a number of laboratories was the causative agent for SARS. The virus was officially named the SARS coronavirus (SARS-CoV). Over 8,000 people were infected, about 10% of whom died.

September 2012
In September 2012, a new type of coronavirus was identified, initially called Novel Coronavirus 2012, and now officially named Middle East respiratory syndrome coronavirus (MERS-CoV). The World Health Organisation issued a global alert soon after. The WHO update on 28 September 2012 stated that the virus did not seem to pass easily from person to person. However, on 12 May 2013, a case of human-to-human transmission in France was confirmed by the French Ministry of Social Affairs and Health. In addition, cases of human-to-human transmission have been reported by the Ministry of Health in Tunisia. Two confirmed cases involved people who seemed to have caught the disease from their late father, who became ill after a visit to Qatar and Saudi Arabia. Despite this, it appears that the virus has trouble spreading from human to human, as most individuals who are infected do not transmit the virus. By 30 October 2013, there were 124 cases and 52 deaths in Saudi Arabia. After the Dutch Erasmus Medical Centre sequenced the virus, the virus was given a new name, Human Coronavirus–Erasmus Medical Centre (HCoV-EMC). The final name for the virus is Middle East respiratory syndrome coronavirus (MERS-CoV). In May 2014, the only two United States cases of MERS-CoV infection were recorded, both occurring in healthcare workers who worked in Saudi Arabia and then traveled to the U.S. One was treated in Indiana and one in Florida. Both of these individuals were hospitalised temporarily and then discharged. In May 2015, an outbreak of MERS-CoV occurred in the Republic of Korea, when a man who had traveled to the Middle East, visited 4 different hospitals in the Seoul area to treat his illness. This caused one of the largest outbreaks of MERS-CoV outside of the Middle East. As of December 2019, 2,468 cases of MERS-CoV infection had been confirmed by laboratory tests, 851 of which were fatal, a mortality rate of approximately 34.5%.

December 2019
On 31 December 2019, a novel strain of coronavirus, officially designated as 2019-nCoV by the World Health Organisation, was reported in Wuhan, China. By 24 January 2020, 25 deaths have been reported and 547 confirmed cases. The Wuhan strain has been identified as a new strain of Betacoronavirus from group 2B with an ~70% genetic similarity to the SARS-CoV. The virus was suspected to have originated in snakes, but many leading researchers disagree with this conclusion.

Further Study
WHO Memos 1972 Explains How To Turn Vaccines Into A Means Of Killing
WHO representative addresses China’s new virus outbreak
Vaccine Adjuvant Squalene, Is It Safe For Elderly Patients?
Bill And Melinda Gates, GAVI, Vaccines And ARK, Absolute Return For Kids
Developing A School Emergency Response Plan Guidance For Governors And Head-Teachers
MI5, Peel Park Primary School, 2009 Contingency Drill And Purves Ali
Holistic Doctors Mysterious Deaths, They Uncovered Cancer Agent In Vaccines
Cancers, Tumours, Autism, Diabetes, What Is Really Going On?
Cancer Epidemic Due To The Introduction Of Viruses Through Vaccinations, SV-40 On Trial
In 2012 Donald Trump Attacked The Vaccination Program Stating Vaccines Cause Autism
Professor Martin Gore CBE Dies In Minutes After Yellow Fever Vaccination
The Liberty Protection Safeguards Give Authority To Kidnap Anyone Into Custody
Whooping Cough Returns In High Vaccinated Areas
Forcing Vaccinations Through The Denial Of Education, 900 Students Suspended
Medicating For The Slave Mentality : Society Of Behavioural Medicine